Physician profile
John Lenahan
NPI 1053391839
$2,841.00
in general payments reported to CMS, 2019-2025
12 companies · $841 in 2025
The $841 reported for 2025 was more than what 98% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $273 · 2023: $803 · 2024: $923 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,567.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $785.38 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $639.59 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $445.86 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $318.66 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $241.96 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.09 | 2022-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $50.63 | 2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $48.95 | 2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $34.98 | 2022-2023 | |
| Mirum Pharmaceuticals, INC. | $20.08 | 2025 | Livmarli |
| Ultragenyx Pharmaceutical INC. | $16.85 | 2022 | |
| Braintree Laboratories, INC. | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lenahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.